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Research on mesenchymal stem cells (MSCs) continues to progress rapidly. Nevertheless, the field faces several challenges, such as
inherent cell heterogeneity and the absence of unique MSCs markers. Due to MSCs’ ability to differentiate into multiple tissues,
these cells represent a promising tool for new cell-based therapies. However, for tissue engineering applications, it is critical to start
with a well-defined cell population. Additionally, evidence that MSCs subpopulations may also feature distinct characteristics and
regeneration potential has arisen. In this report, we present an overview of the identification of MSCs based on the expression
of several surface markers and their current tissue sources. We review the use of MSCs subpopulations in recent years and the
main methodologies that have addressed their isolation, and we emphasize the most-used surface markers for selection, isolation,
and characterization. Next, we discuss the osteogenic and chondrogenic differentiation from MSCs subpopulations. We conclude
that MSCs subpopulation selection is not a minor concern because each subpopulation has particular potential for promoting the
differentiation into osteoblasts and chondrocytes. The accurate selection of the subpopulation advances possibilities suitable for
preclinical and clinical studies and determines the safest and most efficacious regeneration process.
1. Introduction
Stem cells are well defined by their ability to self-renew and to
differentiate into a range of cell types. In the adult organism,
these cells are responsible for maintaining the homeostasis
of their respective tissues. The maintenance of stemness and
pluripotency of stem cells proceeds in the stem cell niche,
where stem cells receive adequate signals from the stroma
and other cell types either via receptors or by secreted soluble
factors within this microenvironmental niche [1].
Mesenchymal stem cells (MSCs) were generally defined
based on their capacity to self-renew and on their phenotype.
The International Society for Cellular Therapy (ISCT) has
proposed the following minimum criteria for the definition
of theMSCs: (I) adherence to plastic surfaces under standard
cell culture conditions; (II) the expression of cell surface
markers, such as CD90, CD73, and CD105, and the lack of
expression of CD14, CD34, CD45, CD79, or CD19 and HLA-
DR, and (III) the capability to differentiate into chondrocytes,
osteoblasts, and adipocytes [2].
Considerable effort has been expended to identify specific
surface markers that characterize MSCs, yet disagreement in
the literature has prevented the creation of definitive stan-
dards. In this regard, additional studies have also associated
othermarkers withMSCs, such as CD271, Stro-1, vascular cell
adhesion molecule-1 (VCAM-1), and CD146 [3–5].
The current review highlights recent findings in the
identification and isolation of MSCs subpopulations, which
could improve expansion strategies in the near future and
the clinical use of MSCs differentiated into osteogenic and
chondrogenic lineages.
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MSCs subpopulations from several sources in conjunc-
tion with specific growth factors and/or scaffold are poten-
tially useful for a variety of clinical orthopedic conditions
involving bone and cartilage. There are several clinical
trials using MSCs subpopulations to repair critical-sized
injuries caused by trauma or infection, aside from replacing
chronically degenerated tissue, such as articular cartilage.
We recognize that variability in MSC-based clinical trial
outcomes is likely due not only to differences amongst various
MSCs sources but also to cell heterogeneity and inadequate
selection of the subpopulation.
2. Sources of Mesenchymal Stem Cells
MSCs were first depicted by Friedenstein et al. in 1968 as
adherent fibroblast-like cells with multipotent differentia-
tion abilities. This study indicated that clonal populations
belonging to the colony forming unit-fibroblastoids (CFU-
Fs) result in osteoblasts, chondrocytes, and hematopoietic
supportive cells in vivo [6]. MSCs were initially isolated from
bone marrow (BM), and, in recent years, the isolation of
adultmesenchymal stem cells fromdifferent sources has been
reported.The comparative quality, character, and differentia-
tion potential of MSCs from each of these sources differ and
are still debated.MSCs have been isolated frommultiple adult
human tissues, such as adipose tissue [7, 8], articular cartilage
[9], brain [10], endometrium [11], menstrual blood [12],
peripheral blood [13], skin and foreskin [14, 15], and synovial
fluid [16]. Additionally, perinatal organs and tissues that are
normally discarded after delivery, namely, amniotic fluid [17],
amnioticmembrane [18, 19], full placenta and fetalmembrane
[20], subamniotic umbilical cord lining membrane [21, 22],
and Wharton’s jelly [23], have been shown to be rich sources
of proliferative MSCs. Other sources include dental tissue,
such as the pulp tissue of permanent human dental pulp
stem cells (DPSCs) [24], stem cells from human exfoliated
deciduous teeth (SHED) [25], periodontal ligament progeni-
tor cells (PDLPs), and PDL stem cells (PDLSCs) [26]. Satellite
cells in muscle and pericytes around blood vessels also share
multipotent characteristics to differentiate into connective
tissue phenotypes under specific conditions [27, 28].
Interestingly, in recent years, the use of bone marrow as a
source of MSCs has decreased. A strong trend is observed in
the use of various postfetal tissues besides adipose tissue as a
major source for isolation.
3. Mesenchymal Stem Cell Subpopulations
MSCs were first identified in the bone marrow as an
adherent population of nonhematopoietic stem cells with
the capability of differentiating into different cell types of
predominantly mesodermal origin. Cultures of MSCs show
high heterogeneity, and the application of MSCs cultures in
tissue regeneration depends mainly on their differentiation
potential. Consequently, researchers are actively attempting
to preselect cell subpopulations with higher osteochondro-
genic potential in order to achieve a thorough translation of
MSC-based therapies for orthopedic applications. Research
over the last years has demonstrated that the use of a specific
MSCs subpopulation ensures successful differentiation into a
particular cell line.
MSCs are classically selected on the basis of their adher-
ence to plastic, which however results in a heterogeneous
population of cells. Prospective identification of the antigenic
profile of the MSCs population (subpopulations) by FACS-
based (fluorescence-activated cell sorting) approaches gives
rise to cells with MSCs activity in vitro and would allow for
the isolation of very pure populations of MSCs for research
or clinical use [29, 30].
Several markers have been proposed to enrich these
subpopulations, but themajority of thesemarkers are defined
for BM. In addition to a phenotypic variation depending
on the MSCs source, the surface markers of freshly isolated
MSCsmay also differ from those of culturedMSCs. Although
there have been attempts to increaseMSCs purity by physical
means, positive selection based on a specific MSCs marker
offers a better alternative. Amongst a number of positive
markers proposed in the past, CD271, CD105, CD44, CD90,
and CD117 seem to offer adequate selectivity. Moreover, the
isolation of homogeneous MSCs is best achieved by cell
sorting with a combination of positive and negative markers.
Blood vessels within skeletal muscle anchor several
precursor populations. It is reported that pericytes, which
surround endothelial cells of capillaries and venules, pos-
sess multipotent differentiation potential [28, 31]. In 2012,
Corselli et al. reported that, in addition to MSCs being
derived from pericytes, adventitial cells could also give rise
to MSCs [32]. In a recent article by Zhao et al., it was
demonstrated that, during incisor trauma, pericytes and
adventitial cells (perivascular stem cells, PSC) are recruited
to modulate hemostasis and repair. Further, in vitro, these
PSC were shown to exhibit typical MSCs features. Sort-
ing pericytes (CD45−/CD146+/CD34−) and adventitial cells
(CD45−/CD146−/CD34+) by FACS is a process that requires
a few hours [33–35] (Figure 1). This isolation method allows
simultaneous purification of three multipotent cell popula-
tions, from three structural layers of blood vessels: pericytes
from media, adventitial cells from adventitia, and myogenic
endothelial cells from intima [36]. More recently, Ko¨nig et al.
enriched a CD146+ subpopulation (CD146+/NG2+/CD45−)
of pericytes from an isolated stromal vascular fraction of
mouse fat tissue and demonstrated its efficient osteoblasts
differentiation in vitro and ability to colonize cancellous
bone scaffolds and regenerate large bone defects in vivo
[37].
In a study conducted by Busser et al. (2015), immunomag-
netic selections with 5 single surfacemarkers were performed
to isolate MSCs subpopulations from BM and adipose tissue
(AT): CD271, SUSD2, MSCA-1, CD44, and CD34. Compared
to the whole population of unselected ADSCs, the authors
observed that CD271 selection can define AT cell population
with highermultipotency and a higher proliferative capability
[38].
Cuthbert et al. used FACS for the isolation of the
subpopulationCD45low/CD73+/CD271+ fromBMphenotype
in order to enrich MSCs fractions. CD271+ immunomag-
netic selection resulted in a substantial increase in MSCs
purity and high expression of bone-related transcripts and
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Figure 1: Pericytes and adventitial cells associated with skeletal
muscle microvessels. A scheme showing the MSC subpopulations
present in the three structural layers of blood vessels: pericytes
(green) from media, adventitial cells (yellow) from adventitia, and
myogenic endothelial cells from intima. Illustration of the pheno-
type of the corresponding cells: pericytes (CD45−/CD146+/CD34−)
and adventitial cells (CD45−/CD146−/CD34+).
vascularization, such as BMP-2, COL1A2, VEGFC, and
SPARC transcripts [39].
Clearly, the use of strategies based on the coexpression
of more than one surface marker improves the purity of the
isolated MSCs population.
Mabuchi et al. (2013) reported in fresh human BM an
improved clonal isolation technique and demonstrated that
the combination of three cell surfacemarkers (LNGFR, THY-
1, and VCAM-1) allows the selection of highly enriched
clonogenic cells. The marker combination LNGFR+/THY-
1+/VCAM-1+ (LTV) represents a valuable strategy for the
isolation of MSCs with broad potentiality features that are
genetically more stable [40].
Likewise, based on the simultaneous use of three stem
cell markers, Leyva-Leyva et al. (2013) selected and sorted
by FACS two homogeneous subpopulations of hMSCs
which coexpress the CD73+/CD44+/CD105+ (6%–12%) or
CD73+/CD44+/CD105− (80%–88%) antigens. This system-
atic method for the isolation of hMSCs generated homoge-
neous cultures for osteoblast differentiationwith an enhanced
ability to mineralize [18].
3.1. Osteogenic Differentiation from Mesenchymal Stem Cell
Subpopulations. Unlikemany other tissues, bone is an excep-
tional tissue that regenerates completely in the absence of
scar tissue [41]. The bone healing process has three stages:
inflammation, bone generation, and bone remodeling.When
the bones fracture, bleeding occurs in the area resulting
in inflammation and blood clotting at the fracture site.
These events provide the primary structural stability and
support for the production of new bone. Following an
inflammatory stage, there is mesenchymal and angiogenic
activation. Blood vessels andMSCs are recruited to the injury
site and proliferate. Afterward, MSCs differentiate into either
chondrocytes or osteoblasts. Mesenchymal cells differentiate
into osteoprogenitors and then proliferate and differentiate
into osteoblasts beginning the production and also secretion
of osteoid, followed by mineralization, a process termed
intramembranous ossification. On the other hand, chon-
drocytes proliferate and mineralize, and next bone tissue is
deposited on the cartilage matrix through a process termed
endochondral ossification. Both processes are completed by
remodeling the bone to restore normal shape and function.
Most of the approaches of bone tissue engineering use
bone marrow-derived cells that are easily accessible, can
differentiate into chondrocytes and osteoblasts in vitro, and
seem to be an ideal autologous cell type [41–44]. Other
autologous cell types such as adipose-derived cells, which are
also very accessible and possess osteogenic and chondrogenic
potential in vitro, represent lately a very attractive source.
Adipose-derived stromal cells (ADSCs) are a very useful
stem cell population, as they are abundant and can be easily
acquired and isolated. However, at the clonal level, only
21% of the population of plastic-adherent ADSCs clones are
determined to be tripotent with an additional 31% and 29%
exhibiting bipotent and unipotent features, respectively [45].
Interestingly, only 48% of the clones are osteogenic, which
means that the surface marker prognostic for osteogenic
potency would improve the efficacy of these cells for bone
tissue engineering.
Stem cell-based bone tissue engineering with ADSCs has
shown great promise for the treatment of large bone deficits.
By FACS, a CD105low cells subpopulation with enhanced
osteogenic differentiation has been identified. Using single-
cell transcriptional analysis, it was found that expression
patterns of the cell surface receptor endoglin (CD105) were
closely associated with the osteogenic potential of ADSCs
(Table 1). By combining microfluidic analysis with FACS,
compared with CD105high and unsorted cells, CD105low
ADSCs were found to be capable of enhanced osteogenic
differentiation [46]. The isolation of ADSCs negative for
CD105 was required to form an osteogenic population. This
approach was based on previous studies which demon-
strated that CD105− ADSCs possess enhanced adipogenic
and osteogenic potential, probably due to the reduced TGF-
𝛽/SMAD2 signaling [46, 47].
Additionally, Leyva-Leyva et al. (2013) positively selected
the surface markers CD73, CD44, and CD105 from human
amniotic membrane by FACS [18]. Two subpopulations with
dissimilar osteoblastic differentiation potential were iso-
lated: CD44+/CD73+/CD105+ (CD105+) and CD44+/CD73+/
CD105− (CD105−). Using in vitro analysis, it was found
that the CD105− MSCs subpopulation was associated with
more effective calcium deposition. Furthermore, through
in vivo trials, it was demonstrated that grafts containing
CD105− promoted adequate graft integration, improved host
vascular infiltration, and showed efficient repair through
intramembranous ossification (Table 1). By contrast, grafts
containing CD105+ showed abundant fibrocartilaginous tis-
sue and deficient endochondral ossification [48].
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Table 1: MSC subpopulations with enhanced osteogenic differentiation.
Subpopulation markers Isolation method Source Reference
CD105low FACS hADSCs Levi et al. 2011 [46]
CD44+/CD73+/CD105− FACS AM-hMSCs Leyva-Leyva et al. 2015 [48]
CD105− Microbeads mADSCs Anderson et al. 2013 [49]
CD105+ Microbeads BM hMSCs
Aslan et al. 2006 [52]
Dennis et al. 2007 [54]
Jarocha et al. 2008 [53]
CD90high FACS Rat dental pulp cells Hosoya et al. 2012 [56]
CD90+ FACS hADSCs Chung et al. 2013 [58]
FACS mADSCs Yamamoto et al. 2014 [50]
SSEA-4+ Magnetic beads hADSCs Mihaila et al. 2013 [59]
CD105+ and CD105− represent independent subpopula-
tions that maintain their properties upon several passages. In
addition to the enhanced osteogenic differentiation potential
of the CD105− subpopulation, Anderson et al. reported
advantageous immunomodulatory properties. Interestingly,
compared to CD105+, CD105− murine-derived MSCs sup-
press the proliferation of CD4+ T cells more efficiently [49].
Meanwhile, in humans, the analysis for HLA system profile
revealed that the CD105− subpopulation lacked HLA-ABC
andHLA-DR (61.65%),which classifies themas nonimmuno-
genically active [18].
It seems that the surface marker CD105 might predict
weak osteogenesis when the source of the isolation is adipose
tissue or amniotic membrane [46, 48, 50]; however, when the
source is bone marrow, conflicting data have been reported
[51].
Aslan et al. found that, in bone marrow, CD105+ cells
displayed enhanced in vitro osteogenic differentiation [52].
Likewise, Jarocha et al. reported that expanded CD105+
populations possess higher expression levels for RUNX2 and
OCN (early and late osteogenic molecular markers, resp.)
[53].
Dennis et al. found that there was good correlation
between in vitro mineralization and in vivo osteogenesis of
CD105+ cells [54]. Interestingly, these authors also observed
a correlation between in vivo bone scores with the presence of
CD105+ cell, suggesting that specific subpopulation seems to
be a key aspect in predicting the osteogenic potential of cells
A second cell surface receptor was also found to correlate
with the expression of osteogenic markers independent
of CD105. CD90 (Thy-1) was originally discovered as a
thymocyte antigen, which could be useful to identify and
isolate ADSCs subpopulations. CD90high ADSCs had greater
reprogramming capacity than CD90low ADSCs, suggesting
that ADSCs have heterogeneous subpopulations [55]. More-
over, Hosoya et al. evaluated the capacity of rat CD90high
and CD90low subodontoblastic dental pulp stem cells to
differentiate into hard tissue-forming cells in response to
bonemorphogenetic protein-2 stimulation and observed that
CD90high had accelerated ability to mineralize in vitro and in
vivo (Table 1) [56].
CD90 and CD105 have been identified as early MSCs
markers present on both BM-MSCs and ADSCs. Chung et
al. demonstrated that, compared with CD90− or unsorted
cells, CD90+ subpopulation isolated from human adipose
tissue has enhanced osteogenic potential in vitro and in
vivo; in fact, the authors proposed CD90 as a better surface
marker to isolate cells with osteogenic potential [57, 58].
Murine-derived ADSCs were sorted for the expression of
the surface markers CD90 and CD105 using flow cytome-
try. ADSCs were sorted into four groups: CD90+/CD105−,
CD90+/CD105+, CD90−/CD105+, and CD90−/CD105−, in
which CD90+/CD105− and CD90+/CD105+ cells had robust
osteogenic potential and displayed mineralized nodules,
whereas strong expression of CD105 might predict weak
osteogenesis [50].
Consistent findings indicate that the absence of CD105
and the expression of CD90 surface markers characterize
subpopulations with increased efficiency of differentiation
into osteogenic lineage.
It has been advised not to discard the possibility of
including other markers as part of an osteogenic profile
analysis. Recently, the expression of the human embryonic
stem cells marker SSEA-4 in a subpopulation of human
adipose tissue (SSEA-4+ hASCs) has been reported. The
subpopulation has the ability to differentiate into osteogenic
lineages but also into endothelial lineages, which represents a
useful approach to obtain these two cell types from the source
and consequently is relevant for bone tissue engineering
applications (Table 1) [59, 60].
3.2. Chondrogenic Differentiation from Mesenchymal Stem
Cell Subpopulations. For clinical success, MSCs must be
held in the area of injury and produce extracellular matrix
in a physiological context, where low nutrient conditions
produced by avascularity, nutrition, andwaste production are
prevalent. CertainMSCs subpopulations aremore resilient to
metabolic challenge than others.
Chondrogenic differentiation of BM-MSCs has been
extensively studied in vitro in micromass pellet, which
promotes cell condensation, aside from cell-cell and cell-
extracellular matrix (ECM) connections [61, 62]. Conse-
quently, cells progress into a highly proliferative stage to
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Table 2: MSC subpopulations with enhanced chondrogenic differentiation.
Subpopulation markers Isolation method Source Reference
CD9+/CD90+/CD166+ FACS SM Fickert et al. 2003 [74]
CD271+ FACS SM Arufe et al. 2010 [76]
Magnetic beads SM Hermida-Go´mez et al. 2010 [78]
CD73+CD39+ FACS SM Gullo and De Bari 2013 [77]
CD105+ Magnetic beads SM Arufe et al. 2009 [79]
CD105− FACS mTPCs Asai et al. 2014 [80]
CD146+ FACS BM Hagmann et al. 2013 [84]
Magnetic beads HU-MSCs Wu et al. 2016 [86]
produce typical components of the cartilaginous matrix
(collagen type 2, collagen type 9, aggrecan, and cartilage
oligomeric matrix protein). Lastly, cells become round and
then go through hypertrophy expressing collagen type X and
MMP13 [63–67].
Cartilage is susceptible to damage and has a reduced
capacity for regeneration. Procedures committed to recruit
stem cells from BM by penetration to the subchondral bone
have been commonly used to treat localized cartilage defects
[68]. More recently, autologous chondrocyte implantation
has been introduced [69]. Research on cartilage tissue engi-
neering in recent years has focused on the use of adult MSCs
as an alternative source of autologous chondrocytes [70].
MSCs can differentiate into chondrocytes and fibrochon-
drocytes, resulting in a combination of cartilaginous fibrous
and hypertrophic tissues, whereby the clinical success lasted
for a short time because these cells do not possess functional
mechanical properties [71]. Conversely, compared to MSCs
derived from BM, MSCs from synovial tissue have been
revealed to enhance chondrogenic potential and diminish the
hypertrophic differentiation [72, 73].
Fickert et al. sorted a triplicate positive subpopula-
tion from the synovial membrane (SM) of patients with
osteoarthritis (CD9+/CD90+/CD166+). In the micromass of
sorted cell cultures, Col2 was located predominantly in the
inner areas, indicating that the subpopulation of SM-derived
cells has the capacity to differentiate efficiently towards the
chondrogenic lineage (Table 2). However, no major differ-
ences between sorted and unsorted SM cells were evidenced
[74, 75].
In 2010, Arufe et al. analyzed the chondrogenic poten-
tial of subpopulations of human synovial membrane MSCs
sorted forCD73,CD106, andCD271markers. Comparedwith
CD106+ and CD271+ subpopulations, CD73+ cells evidenced
the highest expression of SOX9 (a key transcription factor
that is necessary for early chondrogenesis), aggrecan, and
COL2A1 at day 46 of chondrogenic induction. However,
the CD73+ cells also showed the expression of COL10A1,
indicating the presence of hypertrophy during differentiation
[76].
More recently, in 2013, it was reported that the isolation of
a different SM subpopulation based on surfacemarkers CD73
and CD39 displayed consistent dynamics over passaging.The
CD73+CD39+ cell subpopulation displayed higher expression
levels of SOX9 and a significantly greater chondrogenic
potency than the CD73+CD39− cell subpopulation (Table 2)
[77].
Regarding the CD271 surface marker, compared to the
other subpopulations, the CD271+ subpopulation expressed
the highest levels of COL2 staining. Spheroids formed from
CD271+ and CD73+ subpopulations from normal human
synovialmembranes that imitate the native cartilage extracel-
lular matrix more closely than CD106+MSCs, with the result
that both are excellent candidates to use in cartilage tissue
engineering [76].
Hermida-Go´mez et al. strengthened this finding, show-
ing that, during spontaneous cartilage repair, CD271+ pro-
vides higher quality chondral repair than the CD271− sub-
population.The implantation ofMSCsCD271+ provided such
benefits as greater filling of the chondral defect and improved
integration between the repair tissue and native cartilage
(Table 2) [78].
Meanwhile, Arufe et al. reported the isolation by a
magnetic separator of a CD105+ subpopulation from human
synovial membrane. These researchers evidenced a homo-
geneous cellular culture, which expressed Sox9 and had the
ability to develop spheroids after 7 days in the presence
of chondrogenic medium (Table 2). Interestingly, the extra-
cellular matrix produced is rich in Col2 and showed no
evidence of fibrocartilage tissue. The analysis of the CD105−
subpopulation was not reported [79].
Tendon-derived progenitor cells (TPCs) from mice con-
tained two subpopulations: one positive and one negative
for CD105. Compared to the in vitro case with CD105+, the
CD105− negative cells showed superior chondrogenic poten-
tial, and it was proposed that differences in the capability
of chondrogenic differentiation are due to different modes
of smad1/5 and smad2/3 signaling activation as a result of
TGF𝛽s (Table 2) [80].
Various parameters have been considered in hMSCs’
chondrogenic differentiation. In particular, it has been evi-
denced that hMSCs’ expansion in vitro required FGF-2 and
IGF-1 to enhance the proliferative and chondrogenic poten-
tial [81–83]. A highly efficient strategy is based on the pres-
election during the expansion phase of the MSCs by adding
growth factors. In 2013, Hagmann et al. reported that FGF-
2 suppressed CD146 expression and significantly improved
chondrogenic differentiation [84]. Despite the observations
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from the preselection with FGF-2 and resulting suppression
of CD146, in 2014, these researchers demonstrated that,
compared to control MSCs, CD146+ FACS-sorted cells
showed significantly increased GAG/DNA content after
chondrogenic differentiation [85]. It should be noted that
subpopulations, such as CD146+ from human umbilical
cords, not only provide more efficient cartilage regeneration
process but also provide an anti-inflammatory protective
microenvironment resulting from decreased expression of
IL-6 (Table 2) [86].
4. Conclusions
The current review highlights recent findings in the iso-
lation and characterization of MSCs subpopulations and
the potential applications for osteogenic or chondrogenic
differentiation.
It was evident that the source of the MSCs subpopulation
had an effect on the differentiation potential, and certainly
the use of strategies based on the coexpression of more than
one surface marker improves the purity of the isolated MSCs
population.
These findings indicate that the absence of the CD105
surface marker characterizes subpopulations with improved
osteogenesis when the source of isolation is adipose tissue or
amniotic membrane. Furthermore, subpopulations express-
ingCD271 orCD146markers appear to provide higher quality
for chondral repair.
An accurate selection of the subpopulation puts forward
possibilities suitable for preclinical and clinical studies and
determines the safest and most efficacious regeneration
process.
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